Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Henlius logo — Reliable Quality · Affordable Innovation

Henlius

Reliable Quality · Affordable Innovation

Founded 2010 China Shanghai, China 492 employees Venture round Total: $346.00M Biotechnology, Health Care +1

General Information

Company Name Henlius
Founded Year 2010
Location China Shanghai, China
Employees 492
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Henlius. To contact Henlius, visit henlius.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Henlius compare?

A PDF of Henlius and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Henlius soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Henlius

Henlius, founded in 2010, has rapidly emerged as a key player in the biopharmaceutical sector, focusing on oncology. The company's slogan, "Reliable Quality · Affordable Innovation," encapsulates its commitment to delivering high-quality and cost-effective treatments to patients globally.

Headquartered in China, Henlius operates at the intersection of Biotechnology, Health Care, and Pharmaceutical industries. It serves over 950,000 patients across approximately 60 countries, emphasizing its expansive reach and impact.

The company's last major financial injection was a $156.00M venture round investment on 20 July 2018, backed by notable investors such as New China Capital Management, Loyal Valley Capital, CICC, and GreenTomato. Such investment underscores confidence in Henlius's innovative potential and scalability in the pharmaceutical industry.

Business keywords: Biopharmaceutical, Oncology Treatments, Monoclonal Antibodies, Biosimilar Drugs, Bio-betters, Novel mAbs, ADC (Antibody-Drug Conjugates), Immunology, Autoimmune Diseases, Clinical-stage Services, Pharmaceutical Manufacturing, Biotech Innovation, Affordable Treatments, Shanghai Fosun Pharmaceutical

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $156.00M 4
New China Capital Management Loyal Valley Capital CICC
New China Capital Management, Loyal Valley Capital +2
20 Jul 2018
Series B $190.00M 4
GreenTomato
GreenTomato, Joyful Ascent +2
22 Dec 2017
Venture Round Undisclosed 2
Korea Investment Partners Founder H Fund
Korea Investment Partners, Founder H Fund
30 Jun 2016

Henlius Alternatives & Competitors

View All Alternatives
Henlius vs
Harbour BioMed
Harbour BioMed United States

Healthy Life · Breakthrough Medicines

IPO
113 employees
Biopharma, Biotechnology
Compare Henlius vs Harbour BioMed
Henlius vs
BioDlink(TOT BIOPHARM)
BioDlink(TOT BIOPHARM) China

Empowering Pharmaceutical Innovation, Improving Quality of Life, Safeguarding Human Health

Series B
80 employees
Biopharma, Biotechnology
Compare Henlius vs BioDlink(TOT BIOPHARM)
Henlius vs
Novelty Nobility Inc.
Novelty Nobility Inc. Korea South

Novel Science, Noble Management

Series B
10 employees
Biotechnology, Health Care
Also compare with: Henlius vs NBE-Therapeutics AG NBE-Therapeutics AG View all alternatives

FAQ About Henlius

Reliable Quality · Affordable Innovation
Henlius was founded in 2010.
Henlius is headquartered in Shanghai, China.
Henlius operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Biopharmaceutical, Oncology Treatments, Monoclonal Antibodies and Biosimilar Drugs.
Henlius has approximately 492 employees.
Henlius has completed 3 funding rounds, raising a total of $346.00M. The latest funding stage is Venture round.
Top alternatives and competitors to Henlius include Harbour BioMed, BioDlink(TOT BIOPHARM), Novelty Nobility Inc., FatiAbGen Inc., ADC Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Henlius and Harbour BioMed are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Henlius, https://bouncewatch.com/company/henlius, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes